Knut Pettersson

This inventor holds 9 USPTO granted patents and 8 published patent applications, plus 3 CIPO patents and 5 EPO patents. Top assignees: Annexin Pharmaceuticals Ab, Athera Biotechnologies Ab, Dyax Corporation. Active years: 1999-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Knut Pettersson. Retrieved from https://idiyas.com/inventor/knut-pettersson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 9 (Patent Applications = 8)

% Patents Active = 66.7

CIPO Patents = 3 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 6)

Average Co-Inventor Count = 2.8

ph-index = 1

Forward Citations = 4(Granted Patents)

Location History:

Goteborg, SE (1999 - 2000)
Gothenburg, SE (2014 - 2016)
Göteborg, SE (2017 - 2018)

Company Filing History:

5 out of 8

Annexin Pharmaceuticals Ab

patents

2 out of 8

Athera Biotechnologies Ab

The Heart Research Institute Ltd.

patents

where one patent can have more than one assignee

Years Active: 1999-2018

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9901614 - Methods for treating restenosis using annexin A5 (2018-02-27),

2. 9803028 - Antibodies against phosphorylcholine (2017-10-31),

3. 9796786 - Antibodies binding to phosphorylcholine (PC) and/or PC conjugates (2017-10-24),

4. 9682122 - Compounds and methods for the treatment of vascular disease (2017-06-20),

5. 9649355 - Compounds and methods for the treatment of vascular disease (2017-05-16),

6. 9295716 - Methods for treating restenosis using annexin A5 (2016-03-29),

7. 8809497 - Compounds and methods for the treatment of vascular disease (2014-08-19),

8. 6031008 - Method for detection of potential co-antioxidants (2000-02-29),

9. 5883126 - Pharmacological use of certain cystine derivatives (1999-03-16),

Title: Knut Pettersson: Innovator in Medical Treatments

Introduction

Knut Pettersson is a notable inventor based in Göteborg, Sweden. He has made significant contributions to the field of medical treatments, particularly in the area of restenosis and stenosis. With a total of 9 patents, his work has the potential to impact patient care and therapeutic approaches.

Latest Patents

Knut Pettersson's latest patents include innovative methods for treating restenosis using Annexin A5. One of his methods involves administering a therapeutically effective amount of Annexin A5 or a functional analog to patients in need of treatment. Another patent describes a method for treating stenosis in conjunction with administering Annexin A5. Additionally, he has developed a pharmaceutical composition for the prophylaxis or treatment of restenosis and a drug-eluting stent that incorporates Annexin A5. Furthermore, he has patented antibodies against phosphorylcholine, which are capable of binding to phosphorylcholine and its conjugates.

Career Highlights

Throughout his career, Knut has worked with various companies, including Annexin Pharmaceuticals AB and Athera Biotechnologies AB. His expertise in the medical field has allowed him to develop groundbreaking treatments that address critical health issues.

Collaborations

Knut has collaborated with notable coworkers such as Ola Camber and Johan Frostegård. Their combined efforts have contributed to the advancement of medical technologies and therapeutic solutions.

Conclusion

Knut Pettersson's innovative work in medical treatments showcases his dedication to improving patient outcomes. His patents reflect a commitment to addressing significant health challenges through scientific advancements.

Profile summary based on public USPTO records.